Scholar Rock's SMA Drug Approval Timeline Hinges on FDA Catalent Facility Decision
Event summary
- Scholar Rock awaits FDA reclassification of Catalent Indiana's fill-finish facility after April 2026 inspection.
- CHMP opinion for apitegromab MAA could come later in 2026 if FDA reclassifies Catalent Indiana.
- Alternative plan involves using Scholar Rock’s second U.S.-based fill-finish facility if Catalent Indiana is not reclassified.
- Second quarter earnings call on August 6, 2026, will provide further updates.
The big picture
Scholar Rock's progress with apitegromab hinges on regulatory decisions around manufacturing facilities, highlighting the critical role of supply chain readiness in biopharmaceutical approvals. The company’s ability to navigate these challenges will be key as it seeks to expand its presence in treating rare neuromuscular diseases.
What we're watching
- Regulatory Timing
- How the FDA's decision on Catalent Indiana will impact the CHMP opinion timeline for apitegromab.
- Manufacturing Flexibility
- Whether Scholar Rock can smoothly transition to its second fill-finish facility if needed.
- Market Readiness
- The pace at which Scholar Rock can prepare for commercialization pending regulatory approvals.